Skip to content
ΕΛ

PT-141

PT-141

1,267 women, two phase 3 trials, FDA approval in 2019. It doesn't work on the blood vessels — it works in the brain, where desire itself is regulated.

A molecule that works in the head, not the blood vessels. And it does two things: it raises desire and it brings on erections.

Desire. It binds the melanocortin receptors — MC4R — in the medial preoptic area of the hypothalamus, and raises dopamine exactly where interest is regulated 1. This is the axis with phase 3 and FDA approval 3.

And it's appetite, not mechanics. In experimental models it selectively increases initiating behaviors and leaves the reflexes alone 7. It doesn't push the body — it changes the mood.

The erection. A different route from the pills: they work on the blood vessels, this works centrally 8. In healthy volunteers it was significant with no sexual stimulus at all, recorded with an instrument 5. Erectile activity was higher than before, and it rose with the dose 6.

In women. More of them reported moderate or high desire, and those who had sex within 24 hours were satisfied with their arousal 4. The device measuring blood flow saw no difference; the women did 4.

What to expect. Nausea — in 40% with the approved product 2 — and flushing; in phase 3 most adverse events were mild or moderate 3.

Sources — 8 published studies
  1. Pfaus JG, Sadiq A, Spana C, Clayton AH. The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women. CNS Spectr. 2022;27(3):281-289. doi:10.1017/S109285292100002X
  2. Cipriani S, Alfaroli C, Maseroli E, Vignozzi L. An evaluation of bremelanotide injection for the treatment of hypoactive sexual desire disorder. Expert Opin Pharmacother. 2023;24(1):15-21. doi:10.1080/14656566.2022.2132144
  3. Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899-908. doi:10.1097/AOG.0000000000003500
  4. Diamond LE, Earle DC, Heiman JR, Rosen RC, Perelman MA, Harning R. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. J Sex Med. 2006;3(4):628-638. doi:10.1111/j.1743-6109.2006.00268.x
  5. Rosen RC, Diamond LE, Earle DC, Shadiack AM, Molinoff PB. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. Int J Impot Res. 2004;16(2):135-142. doi:10.1038/sj.ijir.3901200
  6. Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 2003;994:96-102. doi:10.1111/j.1749-6632.2003.tb03167.x
  7. Pfaus JG, Shadiack A, Van Soest T, Tse M, Molinoff P. Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. Proc Natl Acad Sci U S A. 2004;101(27):10201-10204. doi:10.1073/pnas.0400491101
  8. King SH, Mayorov AV, Balse-Srinivasan P, Hruby VJ, Vanderah TW, Wessells H. Melanocortin receptors, melanotropic peptides and penile erection. Curr Top Med Chem. 2007;7(11):1098-1106. PMID:17584130

Higher, and with the dose. Erectile activity was higher than before — in healthy men and in patients — and it rose with the dose 4.

No images. No scene. Nothing at all. In healthy volunteers the erection came with sexual stimulus absent, and a machine recorded it — not a questionnaire 3. No pill that works on the blood vessels does that.

In women, it's appetite. 1,267 women, phase 3, FDA approval: desire went up and distress went down 12. And in experimental models it's sexual initiative that rises selectively — not the reflex 5.

What to expect. Nausea and flushing, the most common — in phase 3 most adverse events were mild or moderate 1.

Sources — 6 published studies
  1. Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899-908. doi:10.1097/AOG.0000000000003500
  2. Diamond LE, Earle DC, Heiman JR, Rosen RC, Perelman MA, Harning R. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. J Sex Med. 2006;3(4):628-638. doi:10.1111/j.1743-6109.2006.00268.x
  3. Rosen RC, Diamond LE, Earle DC, Shadiack AM, Molinoff PB. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. Int J Impot Res. 2004;16(2):135-142. doi:10.1038/sj.ijir.3901200
  4. Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 2003;994:96-102. doi:10.1111/j.1749-6632.2003.tb03167.x
  5. Pfaus JG, Shadiack A, Van Soest T, Tse M, Molinoff P. Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. Proc Natl Acad Sci U S A. 2004;101(27):10201-10204. doi:10.1073/pnas.0400491101
  6. King SH, Mayorov AV, Balse-Srinivasan P, Hruby VJ, Vanderah TW, Wessells H. Melanocortin receptors, melanotropic peptides and penile erection. Curr Top Med Chem. 2007;7(11):1098-1106. PMID:17584130

It doesn't open your blood vessels. It switches on your head. The pills you know work on the plumbing. Bremelanotide goes straight to the brain, where desire is born 2.

And this isn't theory: the FDA approved it. 1,267 women, two phase 3 trials, approval in 2019 12. Desire went up — and the distress that came with it went down 1.

Want to see exactly what it wakes up? In experimental models the molecule increases the drive to initiate — the flirting, the move toward the other person — and leaves the reflexes of the act itself untouched 5. It doesn't fix mechanics. It builds appetite.

In men. In healthy volunteers the erection came with no images, no scene, nothing at all — just the molecule, with a machine recording it 3. And it wasn't a one-off moment: erectile activity was higher than before, and it rose with the dose 6.

What to expect. Nausea and flushing are the most common complaints, and in phase 3 most adverse events were mild or moderate 1. In women they also measured it with a machine: the machine saw no difference — the women did 4.

And you take it when you want it. On demand, not every morning for a month 1. For the night that matters to you.

Sources — 6 published studies
  1. Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899-908. doi:10.1097/AOG.0000000000003500
  2. Dhillon S, Keam SJ. Bremelanotide: First Approval. Drugs. 2019;79(14):1599-1606. doi:10.1007/s40265-019-01187-w
  3. Rosen RC, Diamond LE, Earle DC, Shadiack AM, Molinoff PB. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. Int J Impot Res. 2004;16(2):135-142. doi:10.1038/sj.ijir.3901200
  4. Diamond LE, Earle DC, Heiman JR, Rosen RC, Perelman MA, Harning R. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. J Sex Med. 2006;3(4):628-638. doi:10.1111/j.1743-6109.2006.00268.x
  5. Pfaus JG, Shadiack A, Van Soest T, Tse M, Molinoff P. Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. Proc Natl Acad Sci U S A. 2004;101(27):10201-10204. doi:10.1073/pnas.0400491101
  6. Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 2003;994:96-102. doi:10.1111/j.1749-6632.2003.tb03167.x

Frequently asked questions

Which packs is PT-141 available in?

Intro offer: 1 × 10 mg vial · Vial: 10 mg vial · Syringes: 10 × 1 mg syringes, 2 × 1 mg syringes · Pens: 1 × 10 mg pen.

Is PT-141 in stock?

Yes, it ships from stock.

How much is shipping?

€3 shipping + €3 cash-on-delivery fee. For orders of 2 vials or pens or more, shipping and the cash-on-delivery fee are free. Delivery time depends on the courier.

How do I pay?

Cash on delivery, paid to the courier when it arrives. For an electronic money transfer (PayPal, Revolut, Wise, crypto), email us for the details: ellinikapeptidia@gmail.com

Can I return it?

Yes: you have a 14-day right of withdrawal from delivery, as long as the seal is intact. Return costs are yours, unless the product was faulty or wrong. Terms of Use

Want something you don't see here? Write to us — we reply.

Related products

From the same category

Melanotan II
MELANOTAN II

Melanotan II

from €16 to €56

Minimum order 2 vials or 2 pens — delivery in 2 weeks

A tan measured by instrument, not by eye. An α-MSH analogue: it tells melanocytes to make melanin without UV having to ask them to.

1 study
Pack
0
BAC Water
LAB SUPPLIES

BAC Water

€4.80

Water with 0.9% benzyl alcohol — the one thing that lets you open the same vial a second time. The cheapest thing in your cart, and the one that decides whether everything else holds up.

0 studies
Pack
0
Melanotan I
MELANOTAN I

Melanotan I

from €48.80 to €64.80

Minimum order 2 vials or 2 pens — delivery in 2 weeks

The only molecule in this catalog that's an approved drug in the European Union. And that's exactly why we spell out what was approved — and what wasn't.

1 study
Pack
0
SNAP-8
SNAP-8

SNAP-8

from €25.60 to €41.60

Minimum order 2 vials or 2 pens — delivery in 2 weeks

The peptide that mimics how botulinum toxin works — same mechanism, much lower potency. Its real problem isn't whether it works, but whether it gets through the skin.

2 studies
Pack
0
Vesilute
VESILUTE

Vesilute

from €29.60 to €64

Minimum order 2 vials or 2 pens — delivery in 2 weeks

Trade name for the peptide KED (Lys-Glu-Asp) — the same bioregulator tripeptide as Vesugen, in a cosmetic/skin presentation.

1 study
Pack
0
AHK-Cu
AHK-CU

AHK-Cu

from €25.60 to €55.20

Minimum order 2 vials or 2 pens — delivery in 2 weeks

Copper complex (Ala-His-Lys-Cu): at very low concentrations it stimulated elongation of human hair follicles ex vivo and proliferation of dermal papilla cells.

1 study
Pack
0